The Osteogenic Niche Promotes Early-Stage Bone Colonization of Disseminated Breast Cancer Cells

Cancer Cell

Volumn 27, Issue 2, 2015, Pages 193-210

  Wang, Hai ^a   Yu, Cuijuan ^a   Gao, Xia ^a   Welte, Thomas ^a   Muscarella, Aaron M ^a   Tian, Lin ^a   Zhao, Hong ^b   Zhao, Zhen ^b,c   Du, Shiyu ^d   Tao, Jianning ^a   Lee, Brendan ^a   Westbrook, Thomas F ^a   Wong, Stephen T C ^a,b,e   Jin, Xin ^f   Rosen, JeffreyM ^a   Osborne, C Kent ^a   Zhang, Xiang H F ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^d CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^e HOUSTON METHODIST HOSPITAL   (United States)

^f BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; NERVE CELL ADHESION MOLECULE; UVOMORULIN; CADHERIN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; BONE LESION; BONE METASTASIS; BREAST CANCER; CANCER CELL; CELL DISRUPTION; CELL INTERACTION; CELL JUNCTION; CONTROLLED STUDY; DISSEMINATED CANCER; HUMAN; HUMAN CELL; MICROMETASTASIS; MOUSE; NONHUMAN; OSTEOBLAST; PRIORITY JOURNAL; STEM CELL NICHE; STROMA CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; BONE TUMOR; BREAST TUMOR; CANCER STAGING; FEMALE; GENETICS; PATHOLOGY; SECONDARY; TUMOR CELL LINE;

BONE NEOPLASMS; BREAST NEOPLASMS; CADHERINS; CELL LINE, TUMOR; FEMALE; HUMANS; NEOPLASM STAGING; OSTEOGENESIS; TOR SERINE-THREONINE KINASES; TUMOR MICROENVIRONMENT;

EID: 84922804572     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2014.11.017     Document Type: Article

References (50)

1. Aguirre-Ghiso J.A. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 2007, 7:834-846.
2. Bakewell S.J., Nestor P., Prasad S., Tomasson M.H., Dowland N., Mehrotra M., Scarborough R., Kanter J., Abe K., Phillips D., Weilbaecher K.N. Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc. Natl. Acad. Sci. USA 2003, 100:14205-14210.
3. Baron R., Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat. Med. 2013, 19:179-192.
4. Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., Noguchi S., Gnant M., Pritchard K.I., Lebrun F., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N.Engl. J. Med. 2012, 366:520-529.
5. Boulay A., Rudloff J., Ye J., Zumstein-Mecker S., O'Reilly T., Evans D.B., Chen S., Lane H.A. Dual inhibition of mTOR and estrogen receptor signaling invitro induces cell death in models of breast cancer. Clin. Cancer Res. 2005, 11:5319-5328.
6. Buijs J.T., Stayrook K.R., Guise T.A. TGF-β in the bone microenvironment: role in breast cancer metastases. Cancer Microenviron. 2011, 4:261-281.
7. Calvi L.M., Adams G.B., Weibrecht K.W., Weber J.M., Olson D.P., Knight M.C., Martin R.P., Schipani E., Divieti P., Bringhurst F.R., et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003, 425:841-846.
8. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. Cancer Genome Atlas Network.
9. Cawthorn T.R., Amir E., Broom R., Freedman O., Gianfelice D., Barth D., Wang D., Holen I., Done S.J., Clemons M. Mechanisms and pathways of bone metastasis: challenges and pitfalls of performing molecular research on patient samples. Clin. Exp. Metastasis 2009, 26:935-943.
10. Coleman R.E., Guise T.A., Lipton A., Roodman G.D., Berenson J.R., Body J.J., Boyce B.F., Calvi L.M., Hadji P., McCloskey E.V., et al. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin. Cancer Res. 2008, 14:6387-6395.
11. Curtis C., Shah S.P., Chin S.F., Turashvili G., Rueda O.M., Dunning M.J., Speed D., Lynch A.G., Samarajiwa S., Yuan Y., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352. METABRIC Group.
12. Diel I.J., Solomayer E.F., Costa S.D., Gollan C., Goerner R., Wallwiener D., Kaufmann M., Bastert G. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N.Engl. J. Med. 1998, 339:357-363.
13. Dunn L.K., Mohammad K.S., Fournier P.G., McKenna C.R., Davis H.W., Niewolna M., Peng X.H., Chirgwin J.M., Guise T.A. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS ONE 2009, 4:e6896.
14. Eckhardt B.L., Parker B.S., van Laar R.K., Restall C.M., Natoli A.L., Tavaria M.D., Stanley K.L., Sloan E.K., Moseley J.M., Anderson R.L. Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol. Cancer Res. 2005, 3:1-13.
15. Ell B., Kang Y. SnapShot: bone metastasis. Cell 2012, 151:690-690.e1.
16. Fuchs E., Horsley V. Ferreting out stem cells from their niches. Nat. Cell Biol. 2011, 13:513-518.
17. Heller E., Hurchla M.A., Xiang J., Su X., Chen S., Schneider J., Joeng K.S., Vidal M., Goldberg L., Deng H., et al. Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. Cancer Res. 2012, 72:897-907.
18. Herschkowitz J.I., Zhao W., Zhang M., Usary J., Murrow G., Edwards D., Knezevic J., Greene S.B., Darr D., Troester M.A., et al. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc. Natl. Acad. Sci. USA 2012, 109:2778-2783.
19. Hsieh A.C., Costa M., Zollo O., Davis C., Feldman M.E., Testa J.R., Meyuhas O., Shokat K.M., Ruggero D. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010, 17:249-261.
20. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordón-Cardo C., Guise T.A., Massagué J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
21. Kennecke H., Yerushalmi R., Woods R., Cheang M.C., Voduc D., Speers C.H., Nielsen T.O., Gelmon K. Metastatic behavior of breast cancer subtypes. J.Clin. Oncol. 2010, 28:3271-3277.
22. Korpal M., Ell B.J., Buffa F.M., Ibrahim T., Blanco M.A., Celià-Terrassa T., Mercatali L., Khan Z., Goodarzi H., Hua Y., et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat. Med. 2011, 17:1101-1108.
23. Kozlow W., Guise T.A. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J.Mammary Gland Biol. Neoplasia 2005, 10:169-180.
24. Lipton A., Steger G.G., Figueroa J., Alvarado C., Solal-Celigny P., Body J.J., de Boer R., Berardi R., Gascon P., Tonkin K.S., et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J.Clin. Oncol. 2007, 25:4431-4437.
25. Liu S., Ginestier C., Ou S.J., Clouthier S.G., Patel S.H., Monville F., Korkaya H., Heath A., Dutcher J., Kleer C.G., et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 2011, 71:614-624.
26. Long F. Building strong bones: molecular regulation of the osteoblast lineage. Nat. Rev. Mol. Cell Biol. 2012, 13:27-38.
27. Lu X., Mu E., Wei Y., Riethdorf S., Yang Q., Yuan M., Yan J., Hua Y., Tiede B.J., Lu X., et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell 2011, 20:701-714.
28. Lynch M.P., Stein J.L., Stein G.S., Lian J.B. The influence of type I collagen on the development and maintenance of the osteoblast phenotype in primary and passaged rat calvarial osteoblasts: modification of expression of genes supporting cell growth, adhesion, and extracellular matrix mineralization. Exp. Cell Res. 1995, 216:35-45.
29. Mackiewicz-Wysocka M., Pankowska M., Wysocki P.J. Progress in the treatment of bone metastases in cancer patients. Expert Opin. Investig. Drugs 2012, 21:785-795.
30. Minn A.J., Kang Y., Serganova I., Gupta G.P., Giri D.D., Doubrovin M., Ponomarev V., Gerald W.L., Blasberg R., Massagué J. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J.Clin. Invest. 2005, 115:44-55.
31. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2002, 2:584-593.
32. Nieman M.T., Kim J.B., Johnson K.R., Wheelock M.J. Mechanism of extracellular domain-deleted dominant negative cadherins. J.Cell Sci. 1999, 112:1621-1632.
33. Onishi T., Hayashi N., Theriault R.L., Hortobagyi G.N., Ueno N.T. Future directions of bone-targeted therapy for metastatic breast cancer. Nat. Rev. Clin. Oncol. 2010, 7:641-651.
34. Pantel K., Brakenhoff R.H., Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat. Rev. Cancer 2008, 8:329-340.
35. Pantel K., Alix-Panabières C., Riethdorf S. Cancer micrometastases. Nat. Rev. Clin. Oncol. 2009, 6:339-351.
36. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
37. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonetti D.W., Craig S., Marshak D.R. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
38. Schiff R., Massarweh S.A., Shou J., Bharwani L., Mohsin S.K., Osborne C.K. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin. Cancer Res. 2004, 10:331S-336S.
39. Sethi N., Dai X., Winter C.G., Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 2011, 19:192-205.
40. Shiozawa Y., Pedersen E.A., Havens A.M., Jung Y., Mishra A., Joseph J., Kim J.K., Patel L.R., Ying C., Ziegler A.M., et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J.Clin. Invest. 2011, 121:1298-1312.
41. Smid M., Wang Y., Zhang Y., Sieuwerts A.M., Yu J., Klijn J.G., Foekens J.A., Martens J.W. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008, 68:3108-3114.
42. Söderberg O., Gullberg M., Jarvius M., Ridderstråle K., Leuchowius K.J., Jarvius J., Wester K., Hydbring P., Bahram F., Larsson L.G., Landegren U. Direct observation of individual endogenous protein complexes insitu by proximity ligation. Nat. Methods 2006, 3:995-1000.
43. Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98:10869-10874.
44. Straub B.K., Rickelt S., Zimbelmann R., Grund C., Kuhn C., Iken M., Ott M., Schirmacher P., Franke W.W. E-N-cadherin heterodimers define novel adherens junctions connecting endoderm-derived cells. J.Cell Biol. 2011, 195:873-887.
45. Thoreen C.C., Kang S.A., Chang J.W., Liu Q., Zhang J., Gao Y., Reichling L.J., Sim T., Sabatini D.M., Gray N.S. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J.Biol. Chem. 2009, 284:8023-8032.
46. Wang B.T., Ducker G.S., Barczak A.J., Barbeau R., Erle D.J., Shokat K.M. The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile. Proc. Natl. Acad. Sci. USA 2011, 108:15201-15206.
47. Wei G., Twomey D., Lamb J., Schlis K., Agarwal J., Stam R.W., Opferman J.T., Sallan S.E., den Boer M.L., Pieters R., et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006, 10:331-342.
48. Weilbaecher K.N., Guise T.A., McCauley L.K. Cancer to bone: a fatal attraction. Nat. Rev. Cancer 2011, 11:411-425.
49. Wolff A.C., Lazar A.A., Bondarenko I., Garin A.M., Brincat S., Chow L., Sun Y., Neskovic-Konstantinovic Z., Guimaraes R.C., Fumoleau P., et al. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J.Clin. Oncol. 2013, 31:195-202.
50. Zhang X.H., Jin X., Malladi S., Zou Y., Wen Y.H., Brogi E., Smid M., Foekens J.A., Massagué J. Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell 2013, 154:1060-1073.